HGF and Miyoshi myopathy: As shown in Figure 5G, disease burden, HGF release as well as KYN and tryptophan levels were evaluated serially in 1 patient with MM, both before (disease onset) and after treatment (T1 and T2 = 6 months and 1 year, respectively, after combination chemotherapy with bortezomib, melphalan and prednisone).